Prolight on track for clinical performance studies

Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, announces today that their latest data for troponin in whole blood confirm that the company is now ready to initiate trials with patient samples. The latest data were generated in whole blood samples on the final commercial cartridge design, which now includes internal cartridge quality controls […]

Prolight initiates trial at London hospital Trust supported by an NIHR i4i PDA grant

Prolight Diagnostics today announces the company will initiate a trial at Guy’s and St Thomas’NHS Foundation Trust and King’s College London to pre-validate assay and prototype performance of the Psyros™ POC system. The trial is supported by the recently awarded NIHR i4i PDA grant. Initial data with patient samples will be generated in Q3 2024 […]

The exercise period for warrants of series TO6 in Prolight Diagnostics begins today

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Today, […]

Prolight Diagnostics publishes quarterly report Q1, 2024

Financial overview First quarter, January 1 – March 31, Q1 2024 Group(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to SEK 68 (39) thousand. The profit after tax amounted to SEK -8,929 (-7,580) thousand. Earnings per share before and after dilution: […]

Prolight Diagnostics awarded SEK17M UK government grant in collaboration with leading UK hospital Trust

Prolight Diagnostics, developer of the digital point-of-care platform PsyrosTM, has been awarded an NIHR Invention for Innovation (i4i) Product Development Award (PDA) of SEK17M (£1.26M) in collaboration with among others, Guy’s and St Thomas’ NHS Foundation Trust, and King’s College London. “We are delighted to have been awarded this prestigious grant. The National Institute for […]

The exercise price for the warrants of series TO6 in Prolight Diagnostics has been determined to SEK 0.10 per share

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]

Prolight selects MDx CRO for the clinical performance studies for Psyros™

Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, has appointed MDx CRO as its contract research partner for the clinical performance study to validate the Psyros™ high-sensitivity troponin test. After a rigorous selection process, Prolight is pleased to announce the appointment of MDxCRO as its clinical partner. The collaboration will focus on the clinical validation […]

Prolight Diagnostics AB (publ) publishes annual report for 2023

Prolight Diagnostics AB (publ) announces that the annual report for 2023 is now available on the company’s website, https://prolightdx.com/en/investors/financial-reports/ in the attached appendix. For further information, please contact:Prolight Diagnostics AB (publ)E-mail: info@prolightdx.comTelephone: +46 73 582 39 87Website: www.prolightdx.com/en/ About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges […]

NOTICE OF THE ANNUAL GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)

The Company has decided to move the annual general meeting to 27 May 2024. The new notice is stated below, which also replaces the previously published notice. The Company has also decided to move the publication of the Company’s interim report for Q1 to 17 May 2024. The shareholders in Prolight Diagnostics AB (publ), corp. […]

Emergers publishes updated analysis about Prolight Diagnostics

Read the full article at: https://www.emergers.se/prolight_c/ For further information, please contact:Prolight Diagnostics AB (publ)E-mail: info@prolightdx.comTelephone: +46 73 582 39 87Website: www.prolightdx.com/en/ About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.We want to offer the foremost POC […]